Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Tolerability of Rilzabrutinib in Japanese and Caucasian Healthy Subjects
NCT06444191Phase 1Completed
- Sponsor
- Sanofi
- Start
- Jan 2021
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of rilzabrutinib in immune thrombocytopenia (ITP) (2 cohorts), sponsored by Sanofi. Primary endpoints: Maximum measured concentration of total rilzabrutinib in plasma, Time from dosing to maximum measured concentration of total rilzabrutinib in plasma and 8 more. Started Jan 2021; status: completed.
02
Drugs
rilzabrutinib
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT06444191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06444191.